Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FBRX
stocks logo

FBRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2026Q1
--
--
-1.067
-76.49%
--
--
-0.745
-45.62%
Estimates Revision
The market is revising No Change the revenue expectations for Forte Biosciences, Inc. (FBRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 82.59%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+82.59%
In Past 3 Month
Wall Street analysts forecast FBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBRX is 65.00 USD with a low forecast of 65.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBRX is 65.00 USD with a low forecast of 65.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 20.560
sliders
Low
65.00
Averages
65.00
High
65.00
Current: 20.560
sliders
Low
65.00
Averages
65.00
High
65.00
Evercore ISI
Outperform
initiated
$65
2025-11-25
Reason
Evercore ISI
Price Target
$65
2025-11-25
initiated
Outperform
Reason
Evercore ISI initiated coverage of Forte Biosciences with an Outperform rating and $65 price target. There has been a notable re-rating in development-stage microcap companies, especially those with important proof of concept data in 2025 and 2026, notes the analyst. While arguing that Forte "falls squarely in this bucket," the firm notes shares have been slow to get the same bid until the last two weeks, adding that it thinks the setup is "super attractive into a catalyst-rich 2026."
Guggenheim
NULL -> Buy
initiated
$75
2025-08-18
Reason
Guggenheim
Price Target
$75
2025-08-18
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of Forte Biosciences with a Buy rating and $75 price target.
Guggenheim
NULL -> Buy
initiated
$75
2025-08-18
Reason
Guggenheim
Price Target
$75
2025-08-18
initiated
NULL -> Buy
Reason
As previously reported, Guggenheim initiated coverage of Forte Biosciences with a Buy rating and $75 price target, citing a positive view of CD122-blockade as a therapeutic opportunity across a number of severe autoimmune diseases. If approved, the firm estimates about $2.6B risk-unadjusted global peak sales for FB102 across the three autoimmune diseases of celiac disease, vitiligo, and alopecia areata, says the analyst, who expects shares to outperform given three clinical potential catalysts expected in 2026.
Lucid Capital
NULL -> Buy
initiated
$28
2025-06-05
Reason
Lucid Capital
Price Target
$28
2025-06-05
initiated
NULL -> Buy
Reason
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$64 → $61
2025-04-01
Reason
Chardan Capital
Daniil Gataulin
Price Target
$64 → $61
2025-04-01
Maintains
Strong Buy
Reason
TD Cowen
Yaron Werber
Strong Buy
Initiates
n/a
2025-01-21
Reason
TD Cowen
Yaron Werber
Price Target
n/a
2025-01-21
Initiates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Forte Biosciences Inc (FBRX.O) is -6.33, compared to its 5-year average forward P/E of -5.00. For a more detailed relative valuation and DCF analysis to assess Forte Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.00
Current PE
-6.33
Overvalued PE
3.08
Undervalued PE
-13.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.49
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.39
Undervalued EV/EBITDA
-6.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

FBRX News & Events

Events Timeline

(ET)
2025-11-14
09:02:35
Forte Biosciences Announces Q3 Earnings Per Share of 99 Cents, Below Consensus Estimate of $1.07
select
2025-08-14 (ET)
2025-08-14
16:02:10
Forte Biosciences reports Q2 EPS (96c), consensus ($1.11)
select
2025-06-24 (ET)
2025-06-24
16:02:13
Forte Biosciences announces common stock offering, no amount given
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-17Benzinga
Chardan Capital Reaffirms Buy Rating for Forte Biosciences with $61 Price Target

  • Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders make informed decisions.

  • Exclusive Stories: The platform provides exclusive news stories generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing insights and strategies.

  • Trade Alerts: Users can receive the fastest news alerts to ensure they never miss a trading opportunity.

[object Object]
Preview
5.0
10-04Newsfilter
Forte Biosciences, Inc. Announces Inducement Grants in Compliance with Nasdaq Listing Regulations

  • Equity Inducement Awards: Forte Biosciences announced the issuance of equity inducement awards, granting options to purchase 125,000 shares of common stock to new non-executive employees as part of their employment agreement.

  • Vesting Schedule: The options will vest over four years, with 25% vesting after one year and the remaining 75% vesting in monthly increments, contingent on the employees' continuous employment.

  • Company Overview: Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing FB102, a proprietary anti-CD122 monoclonal antibody for autoimmune and related diseases.

  • Regulatory Compliance: The equity awards were issued in compliance with NASDAQ Listing Rule 5635(c)(4) and are part of Forte's 2020 Inducement Equity Incentive Plan.

[object Object]
Preview
9.0
09-15Newsfilter
Forte Biosciences, Inc. to Present FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

  • FB102 Clinical Trial Results: Forte Biosciences presented promising results for FB102 in a phase 1b study for celiac disease, showing significant reductions in TCR γδ cell density and Ki67-positive intraepithelial cell density compared to placebo, indicating a potential therapeutic effect.

  • Future Developments: The company is advancing to a phase 2 trial for FB102, with topline data expected in 2026, and is also exploring additional therapeutic indications for conditions like vitiligo and alopecia areata, with data anticipated next year.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Forte Biosciences Inc (FBRX) stock price today?

The current price of FBRX is 20.56 USD — it has increased 12.29 % in the last trading day.

arrow icon

What is Forte Biosciences Inc (FBRX)'s business?

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.

arrow icon

What is the price predicton of FBRX Stock?

Wall Street analysts forecast FBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBRX is 65.00 USD with a low forecast of 65.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Forte Biosciences Inc (FBRX)'s revenue for the last quarter?

Forte Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Forte Biosciences Inc (FBRX)'s earnings per share (EPS) for the last quarter?

Forte Biosciences Inc. EPS for the last quarter amounts to -0.99 USD, decreased -78.19 % YoY.

arrow icon

What changes have occurred in the market's expectations for Forte Biosciences Inc (FBRX)'s fundamentals?

The market is revising No Change the revenue expectations for Forte Biosciences, Inc. (FBRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 82.59%.
arrow icon

How many employees does Forte Biosciences Inc (FBRX). have?

Forte Biosciences Inc (FBRX) has 14 emplpoyees as of December 05 2025.

arrow icon

What is Forte Biosciences Inc (FBRX) market cap?

Today FBRX has the market capitalization of 257.05M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free